AI Terminal
Pharmanutra
M&A Activity • Jun 15, 2022
4324_tar_2022-06-15_48a01b95-6e90-445f-b38e-89afe147ad2a.pdf
M&A Activity
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 20106-44-2022 |
Data/Ora Ricezione 15 Giugno 2022 15:16:30 |
Euronext Star Milan | |
|---|---|---|---|
| Societa' | : | PHARMANUTRA | |
| Identificativo Informazione Regolamentata |
: | 163667 | |
| Nome utilizzatore | : | PHARMANUTRAN04 - Roberto Lacorte | |
| Tipologia | : | REGEM | |
| Data/Ora Ricezione | : | 15 Giugno 2022 15:16:30 | |
| Data/Ora Inizio Diffusione presunta |
: | 15 Giugno 2022 15:16:31 | |
| Oggetto | : | PHARMANUTRA: Signing of the agreement for the acquisition of 100% of Akern S.r.l. |
|
| Testo del comunicato |
Vedi allegato.
PHARMANUTRA: SIGNING OF THE AGREEMENT FOR THE ACQUISITION OF 100% OF AKERN S.R.L.
Pisa, June, 15, 2022 – PharmaNutra S.p.A. (MTA; Ticker PHN), a company specialized in nutritional supplements, based on iron and minerals and medical devices for muscles and joints, is pleased to announce the signing of the contract for the acquisition from Red Lions S.p.A., Jacopo Talluri and Liside S.r.l., of the 100% of Akern S.r.l. – growing player active in the R&D, production and commercialization of medical devices and software for the monitoring of the body composition through bio-impedance techniques.
The acquisition price for the 100% equity shares of Akern is EUR 12 million, excluding an earn-out to the sellers for a maximum of EUR 3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024.
The closing is subject, among others, to the "Golden Power" authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern's equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern's equity.
Andrea Lacorte, Chairman of Pharmanutra S.p.A., commented:
"The acquisition of Akern represents a turning point for both the companies and a key milestone in the implementation of PharmaNutra's growth strategy. Akern is a cash generating company with a growing business which will allow the realization of important strategic synergies, starting from 2023, with a boost and diversification of the business lines. Pharmanutra will heavily strengthen its know how benefiting from more than 40 years' experience of a leading Italian company in the bio-impedance analysis, and it will support Akern in consolidating its presence in the Italian and International markets through our capillary network of distributors.
Synergies – concluded Mr. Lacorte – aimed to increase exponentially the competitiveness, with enormous growth opportunities and value creation for the shareholders."
PharmaNutra S.p.A.
Established and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated by a wealth of scientific evidence, including 135 publications with over 7,000 subjects involved. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is carried out through a network of over 160 Scientific Sales Representatives at the service of the medical class, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 60 countries through 42 partners selected among the leading pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL®, for which it boasts key patents for the Sucrosomial® Technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.
For further details:
Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 [email protected]
Internal Press Office [email protected]
PharmaNutra S.p.A. Press Office - Spriano Communication & Partners
Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708
Matteo Russo [email protected] Cristina Tronconi [email protected]
